Evidence map›Paper›PMID 42665162›Full record

ReviewJournal of lipid research2026

Biosynthesis and analytics of specialized pro-resolving mediators: facts and faults.

Nils Helge Schebb, Hartmut Kühn, Nadja Kampschulte, Nicolas Flamand, Marc Peters-Golden, Per-Johan Jakobsson, Hans-Erik Claesson, Karsten H Weylandt, Nadine Rohwer, Meike J Saul and 24 more

Abstract readReview
In one paragraph

Review in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Nils Helge SchebbFood Chemistry, Faculty of Mathematics and Natural Sciences, University of Wuppertal, Wuppertal, Germany. Electronic address: nils@schebb-web.de.
Hartmut KühnDepartment of Biochemistry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Nadja KampschulteFood Chemistry, Faculty of Mathematics and Natural Sciences, University of Wuppertal, Wuppertal, Germany.
Nicolas FlamandCentre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Département de médecine, Faculté de médecine, Université Laval, Québec City, Quebec, Canada.
Marc Peters-GoldenDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Per-Johan JakobssonDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet & Karolinska University Hospital, Center for Molecular Medicine, Stockholm, Sweden.
Hans-Erik ClaessonDepartment of Medicine, Karolinska University Hospital Solna, Stockholm, Sweden.
Karsten H WeylandtDivision of Gastroenterology & Endocrinology and Nutrition Skills Lab, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, Germany; Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Brandenburg Medical School and University of Potsdam, Potsdam, Germany.
Nadine RohwerDivision of Gastroenterology & Endocrinology and Nutrition Skills Lab, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, Germany; Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Brandenburg Medical School and University of Potsdam, Potsdam, Germany; Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Meike J SaulDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Eugen ProschakInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology, ITMP and Fraunhofer Cluster of Excellence for Immune mediated diseases, CIMD, Frankfurt am Main, Germany.
Bernhard BrüneInstitute of Biochemistry I, Faculty of Medicine, Goethe University Frankfurt, Frankfurt, Germany.
Ulrike GarschaDepartment of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Greifswald University, Greifswald, Germany.
Thorsten J MaierDepartment of Immunology, Paul-Ehrlich-Institute (Federal Institute for Vaccines and Biomedicines), Langen, Germany.
Paola PatrignaniDepartment of Neuroscience, Imaging and Clinical Sciences, and Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University, Chieti, Italy.
Miguel A GijónCayman Chemical Company, Ann Arbor, MI, USA.
Francisco J SchopferDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.
Stacy L GelhausDepartment of Pharmacology and Chemical Biology, Health Sciences Mass Spectrometry Core, University of Pittsburgh, Pittsburgh, PA, USA.
Michael H GelbDepartment of Chemistry and Biochemistry, University of Washington, Seattle, WA, USA.
Robert C MurphyDepartment of Pharmacology, University of Colorado-Denver, Aurora, CO, USA.
Carsten SkarkeInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alan R BrashDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.
Bruce A FreemanDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.
Ian A BlairPenn/CHOP Friedreich Ataxia Center of Excellence, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Derek W GilroyDept. of Ageing, Rheumatology and Regenerative Medicine, University College London, London, UK.
Gerd GeisslingerInstitute of Clinical Pharmacology, Faculty of Medicine, Goethe-University Frankfurt, Frankfurt am Main, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology, ITMP and Fraunhofer Cluster of Excellence for Immune mediated diseases, CIMD, Frankfurt am Main, Germany.
Julien HansonLaboratory of Molecular Pharmacology, GIGA Research Institute & CIRM, University of Liège, Liège, Belgium.
Kim EkroosLipidomics Consulting Ltd., Esbo, Finland.
Garret A FitzGeraldInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Astrid S KahntInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, Germany.
Valerie B O'DonnellSystems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, UK. Electronic address: O-DonnellVB@cardiff.ac.uk.
Mohamad Wessam AlnouriMax Planck Institute for Heart and Lung Research, Department of Pharmacology, Bad Nauheim, Germany.
Stefan OffermannsMax Planck Institute for Heart and Lung Research, Department of Pharmacology, Bad Nauheim, Germany; Center for Molecular Medicine, Goethe University Frankfurt, Frankfurt, Germany. Electronic address: stefan.offermanns@mpi-bn.mpg.de.
Dieter SteinhilberInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology, ITMP and Fraunhofer Cluster of Excellence for Immune mediated diseases, CIMD, Frankfurt am Main, Germany. Electronic address: steinhilber@em.uni-frankfurt.de.

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
Formation and metabolism of nitrated fatty acidsR01GM125944 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCHOPFER, FRANCISCO JOSE · 2018 to 2025
$3.4M
Impact of dietary lipid components on phototherapy used to treat inflammatory skin conditionsR01AR084311 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ALICIA R MATHERS, Francisco Jose Schopfer · 2025 to 2026
$1.3M
Analytical approaches to fatty acid oxygenases and their lipid mediator productsR35GM152031 · NIGMS · VANDERBILT UNIVERSITY · PI ALAN R. BRASH · 2024 to 2026
$1.2M
An Exploris 240 for MetabolomicsS10OD032141 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GELHAUS, STACY LYNN · 2022 to 2022
$600k
Bringing Untargeted Metabolomics to PittS10OD023402 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GELHAUS, STACY LYNN · 2018 to 2018
$594k
NCATS NIH HHS UL1 TR001878NIAMS NIH HHS R01 AR084311NIGMS NIH HHS R01 GM125944NIGMS NIH HHS R35 GM152031NIH HHS S10 OD023402NIH HHS S10 OD032141
6 · The paper itself

Abstract

Specialized pro-resolving mediators (SPMs) have been suggested to act as key factors that mediate the resolution of inflammation. With the availability of synthetic standards, pharmacological studies have garnered support for the hypothesis. However, assessment of the catalytic properties of lipoxygenases as well as investigations of the signaling of the proposed SPM receptors raise serious doubt that SPMs are endogenous mediators of the resolution of inflammation. In line with this, careful evaluation of published data on SPM detection revealed a lack of evidence for many reported SPMs in biological samples due to analytical LC-MS/MS methods that do not meet the quality standards of the scientific community, or they rely on ELISAs that lack selectivity and are not suited for the establishment of the presence of SPMs in complex biological samples. Furthermore, artefacts due to autoxidation of PUFAs can be misinterpreted as SPM formation. In this review, we critically assess the published reports on the biosynthesis and analysis of SPMs and summarize the current status in the field.

Indexed as

leukotrienelipoxinlipoxygenaseresolutionresolvingSPM receptor

Identifiers

PMID42665162
PMCPMC13658875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.